Compare · Health Care
Johnson & Johnson vs. Pfizer: how they make money
The same facts for both companies, in the same order, from each company's own page and filings. It is not a ranking.
How they differ
In FY2025, Johnson & Johnson's revenue of $94.2B was about 1.5 times Pfizer's $62.6B (Cityfort calculation: one divided by the other).
Johnson & Johnson's largest segment is Innovative Medicine, 64.1% of revenue in FY2025; Pfizer's largest segment is Primary Care, 42.9% of revenue in FY2025.
United States brought in 57.1% of Johnson & Johnson's revenue in FY2025; United States brought in 59.2% of Pfizer's revenue in FY2025.
Johnson & Johnson's largest payer group is Customers in the US, 57.1% of revenue (FY2025); Pfizer's largest payer group is Customers in the US, 59.2% of revenue (FY2025).
Neither page lists the other among its competitors.
Each company in 5 points
Johnson & Johnson
1 · What it sells
Johnson & Johnson sells prescription medicines and medical devices, with FY2025 sales of $60.4 billion and $33.8 billion, or $94.2 billion in total.
Sources and detail on the Johnson & Johnson page2 · Who pays it
Johnson & Johnson reports no revenue by final payer and three wholesalers were 48.4 percent of gross revenues; by location, in FY2025 the US was 57.1% of sales, Europe 22.9%, Asia-Pacific and Africa 14.9% and the rest of the Western Hemisphere 5.2%.
Sources and detail on the Johnson & Johnson page3 · What it keeps from $100
Of every $100 that came in during FY2025, J&J kept $26.2 as net income, helped by a one-off talc reserve reversal of about $7.0 billion, while operating income, a Cityfort calculation from the FY2025 10-K, was $26.85 per $100 of sales.
Sources and detail on the Johnson & Johnson page4 · Where the operating profit comes from
Medicines made 84.4% of the two segments' FY2025 income before tax on 64.1% of sales, and devices made 15.6% on 35.9%; J&J reports no operating income by segment.
Sources and detail on the Johnson & Johnson page5 · The one thing to watch
About 76,500 US plaintiffs had pending talc lawsuits at Sep 27, 2026, and J&J's proposed $5.5 billion ovarian claims resolution needs at least 95% of remaining claims to take part.
Sources and detail on the Johnson & Johnson page
Pfizer
1 · What it sells
Pfizer sells medicines and vaccines worldwide, and 12 products of more than $1 billion each were 65% of its $62.6 billion of FY2025 revenue.
Sources and detail on the Pfizer page2 · Who pays it
Pfizer reports no revenue by final payer and three US wholesalers bought 54 percent; by location, in FY2025 the US paid 59.2% of revenue, other developed markets 25.9% and emerging markets 14.9%.
Sources and detail on the Pfizer page3 · What it keeps from $100
Of every $100 of FY2025 revenue, Pfizer kept $12.4 as net income, after $10.7 of other deductions that included $7.8 of impairment charges, and with a $0.4 tax benefit; operating income, a Cityfort calculation from the FY2025 10-K, was $22.8.
Sources and detail on the Pfizer page4 · Where the operating profit comes from
Biopharma, Pfizer's one reportable segment, earned $29.3 billion in FY2025 before amortization and other items, other activities lost $8.2 billion, and Pfizer gives no earnings by product group.
Sources and detail on the Pfizer page5 · The one thing to watch
Settled generic companies may launch Eliquis, Pfizer's largest product at $8.0 billion of FY2025 revenue, in the US from Apr 1, 2028, and Pfizer said on Nov 3, 2026 that it expects generic and biosimilar competition to cost about $1.1 billion of 2026 revenue.
Sources and detail on the Pfizer page
Where each $100 went
Each company's own receipt for its latest full fiscal year, with matching lines in the same order where both have them.
Johnson & Johnson
Where $100 went · FY2025
| Cost of making products | $29.5 |
|---|---|
| Research and development | $14.3 |
| Selling, marketing and admin | $23.1 |
| Restructuring and research write-downs | $0.3 |
| Interest expense | $0.9 |
| Income tax | $5.6 |
| Kept as net income | $26.2 |
| Total | $100 |
Cityfort calculation from the FY2025 10-K. Of every $100 that came in during FY2025 (sales of $94.2 billion plus $8.3 billion of interest and other income): each line = line ÷ $102.5 billion × 100. Interest and other income were $8.1 of each $100, and included the about $7.0 billion talc reserve reversal.
Pfizer
Where $100 went · FY2025
| Cost of making products | $25.7 |
|---|---|
| Research and development | $16.7 |
| Selling, informational and admin | $22.0 |
| Other deductions (impairments, interest, legal) | $10.7 |
| Amortization of bought rights | $7.8 |
| Research bought from others (acquired IPR&D) | $2.6 |
| Restructuring and deal costs | $2.5 |
| Tax benefit and small items (adds) | −$0.4 |
| Kept as net income | $12.4 |
| Total | $100 |
Cityfort calculation from the FY2025 10-K. Of every $100 of revenue in FY2025: each line = line ÷ $62.6 billion × 100. Net other items were a cost, so no other income is added. Other deductions include $7.8 of intangible asset impairments ($4.9 billion). The tax line is a benefit, so it adds $0.4.
Line items differ because each company groups its costs its own way in its filings. Only on Johnson & Johnson's receipt: Selling, marketing and admin; Restructuring and research write-downs; Interest expense; Income tax. Only on Pfizer's receipt: Selling, informational and admin; Other deductions (impairments, interest, legal); Amortization of bought rights; Research bought from others (acquired IPR&D); Restructuring and deal costs; Tax benefit and small items (adds).
Revenue, net income and free cash flow
Up to five fiscal years for each company, drawn on one shared scale per measure. Amounts in US$ as reported (GAAP).
Revenue
Johnson & Johnson
Pfizer
See the numbers
Net income
Johnson & Johnson
Pfizer
See the numbers
Free cash flow
Johnson & Johnson
Pfizer
See the numbers
Growth and net margin, FY2021 to FY2025
Worked out over the years both pages cover, so the two growth figures use the same span. Net margin is net income as a share of revenue, as on each page.
Johnson & Johnson
- Revenue, per year
- +4.6%
- Net income, per year
- +10.8%
Pfizer
- Revenue, per year
- −6.3%
- Net income, per year
- −22.9%
Cityfort calculation: compound growth per year from FY2021 to FY2025 (4 years), from each page's yearly numbers, as reported.
Net margin by year
Latest quarter, against the same quarter a year earlier
Each page's latest quarter as reported; the change is a Cityfort calculation.
Johnson & Johnson
Q3 FY2026, the quarter to Sep 27, 2026, against Q3 FY2025
| Measure | Q3 FY2026 | Q3 FY2025 | Change |
|---|---|---|---|
| Revenue | $25.4B | $24.0B | +5.9% |
| Net income | $210M | $5.2B | −95.9% |
Pfizer
Q3 FY2026, the quarter to Sep 27, 2026, against Q3 FY2025
| Measure | Q3 FY2026 | Q3 FY2025 | Change |
|---|---|---|---|
| Revenue | $16.6B | $16.7B | −0.4% |
| Net income | $3.2B | $3.5B | −8.4% |
Sources: Johnson & Johnson S22, S9, S10, S20, S1, S18, S8, S16, S7, S14, S6 · Pfizer S16, S9, S15, S1, S14, S8, S13, S7, S12, S6
Who pays each company
Johnson & Johnson
- Customers in the US · 57.1% of revenue57.1% of FY2025 sales ($53.8 billion). Shares here are by location, because J&J does not report revenue by final payer.
- Customers in Europe · 22.9% of revenue22.9% of FY2025 sales ($21.5 billion).
- Customers in Asia-Pacific and Africa · 14.9% of revenue14.9% of FY2025 sales ($14.0 billion).
- Customers in the Western Hemisphere outside the US · 5.2% of revenue5.2% of FY2025 sales ($4.9 billion).
Pfizer
- Customers in the US · 59.2% of revenue59.2% of FY2025 revenue ($37.1 billion). Most US sales go through wholesalers, while Medicare, Medicaid and contract payers take rebates. Shares here are by location, because Pfizer does not report revenue by final payer.
- Customers in other developed markets · 25.9% of revenue25.9% of FY2025 revenue ($16.2 billion).
- Customers in emerging markets · 14.9% of revenue14.9% of FY2025 revenue ($9.3 billion). China, the largest country outside the US, was 5% of total revenue.
Revenue by segment
Johnson & Johnson
FY2025
| Segment | Revenue | Share |
|---|---|---|
| Innovative Medicine | $60.4B | 64.1% |
| MedTech | $33.8B | 35.9% |
Pfizer
FY2025
| Segment | Revenue | Share |
|---|---|---|
| Primary Care | $26.8B | 42.9% |
| Specialty Care | $17.5B | 28.0% |
| Oncology | $16.8B | 26.9% |
| Other business activities | $1.4B | 2.2% |
Where the revenue comes from
Revenue by region, as each company splits it, with the period.
Johnson & Johnson
FY2025
- United States57.1%
- Europe22.9%
- Asia-Pacific and Africa14.9%
- Western Hemisphere outside the US5.2%
Pfizer
FY2025
- United States59.2%
- Other developed markets25.9%
- Emerging markets14.9%
Debt and cash
Johnson & Johnson
- Debt
- $44.7B
- Cash and investments
- $17.2B
On Sep 27, 2026.
J&J states net debt of $27.4 billion at Sep 27, 2026 in its 10-Q. That is about 1.05 times operating cash flow over the last four quarters (Cityfort calculation from the FY2025 10-K, Q3 FY2025 10-Q and Q3 FY2026 10-Q).
Pfizer
- Debt
- $62.7B
- Cash and investments
- $14.3B
On Sep 27, 2026.
At Sep 27, 2026 Pfizer's debt exceeded its cash and short-term investments by $48.4 billion, down from $51.2 billion at Dec 31, 2025. That is about 3.4 times operating cash flow over the last four quarters (Cityfort calculation from the FY2025 10-K, Q3 FY2025 10-Q and Q3 FY2026 10-Q).
Sources: Johnson & Johnson S6, S1, S3, S9 · Pfizer S6, S1, S9, S3, S4
Who owns each company
Johnson & Johnson
- One class of shares.
- Officers and directors as a group: 0.2% of shares (as of Feb 24, 2026).
- BlackRock, Inc.: 7.7% (as of Jan 26, 2024).
- Vanguard Capital Management: 7.5% (as of May 1, 2026).
- State Street Corporation: 5.5% (as of Jan 30, 2024).
- 1 more holders on the Johnson & Johnson page.
Pfizer
- One class of shares.
- Officers and directors as a group: 0.0% of shares (as of Jan 31, 2026).
- BlackRock, Inc.: 7.7% (as of Jan 26, 2024).
- Vanguard Capital Management: 7.5% (as of May 1, 2026).
- State Street Corporation: 5.1% (as of Jan 29, 2024).
- 1 more holders on the Pfizer page.
Sources: Johnson & Johnson S31, S6, S42 · Pfizer S20, S1, S6, S21
What protects each business
What each page lists as protecting the business from competitors, each with its written reason. These describe business traits, not the share.
Johnson & Johnson
- Research spending
J&J spent $14.7 billion on research and development in FY2025, or 15.6% of sales. It also bought research assets, such as Firefly Bio for about $1.0 billion in 2026.
- Two businesses
Medicines were 64.1% and devices 35.9% of FY2025 sales. Immunology sales fell 11.8% in FY2025, and total sales still rose 6.0%.
- Global reach
Customers outside the US were 42.9% of FY2025 sales (Cityfort calculation from the FY2025 10-K), and J&J ran 63 manufacturing facilities, 22 of them in the US.
- Patents on the main medicines
A Tremfya patent family is projected to run to 2031 in the US. The Darzalex families expire in the US in 2029, and biosimilars of Stelara have launched.
- Pricing power
Price lowered FY2025 sales growth by 3.1%, while volume added 8.4%. Medicare negotiated prices for Xarelto, Stelara and Imbruvica started in 2026.
Pfizer
- Range of products
Twelve products each brought in more than $1 billion in FY2025 and were 65% of revenue. The largest, Eliquis, was 13%.
- Research spending
Pfizer spent $10.4 billion on research and development in FY2025, 16.7% of revenue, plus $1.6 billion on acquired research.
- Global reach
Revenue exceeded $500 million in each of 12 countries outside the US in 2025, and 40.8% of FY2025 revenue came from outside the US.
- Patents on the main medicines
Basic US patents on Padcev and Lorbrena run to 2033 and Prevnar 20 to 2035. Those on Ibrance and Xtandi run to 2027, and settled generic companies may launch Eliquis from Apr 1, 2028.
- Pricing power
Medicare set a negotiated Eliquis price from Jan 1, 2026, with Ibrance and Xtandi following in 2027. Pfizer also agreed with the US government to make certain prices more comparable to other developed countries.
Where growth could come from
Each page's growth drivers. The status compares progress with what the company itself said it would do; it is not a view on the share.
Johnson & Johnson
- Darzalex · Working: on track against what the company said$4.2B in Q3 FY2026, up 15.4%
- Tremfya · Working: on track against what the company said$2.4B in Q3 FY2026, up 68.3%
- Carvykti · Working: on track against what the company said$710M in Q3 FY2026, up 35.5%
- Neuroscience · Working: on track against what the company said$2.4B in Q3 FY2026, up 17.3%
- Cardiovascular devices · Mixed: partly on track$2.3B in Q3 FY2026, up 4.3%
- Ottava surgical robot · New: recently announcedFDA authorized in Q3 FY2026
- Firefly Bio and Sail Biomedicines · Early: too early to judgeAbout $1.0B and $0.8B paid in Q3 FY2026
Pfizer
- Eliquis · Mixed: partly on track$2.5B in Q3 FY2026, up 25%
- Vyndaqel family · Working: on track against what the company said$1.8B in Q3 FY2026, up 11%
- Padcev · Working: on track against what the company said$720M in Q3 FY2026, up 55%
- Nurtec · Working: on track against what the company said$547M in Q3 FY2026, up 33%
- Obesity programs from Metsera · Early: too early to judge10 Phase 3 studies planned in 2026
- Licensed-in cancer programs · New: recently announced$650M paid to Innovent in 2026
- Cost programs · Working: on track against what the company said$5.1B saved through 2025
Sources: Johnson & Johnson S6, S1, S13, S33 · Pfizer S12, S6, S1, S13, S3, S4, S27
Dividends, buybacks, auditor and credit rating
Dividends per share and buybacks for up to five years, the independent auditor and the latest credit rating, as each page records them.
Johnson & Johnson
- Dividends per shareFY2021: $4.19 (62.0% of profit) · FY2022: $4.45 (71.4% of profit) · FY2023: $4.70 (88.3% of profit) · FY2024: $4.91 (84.1% of profit) · FY2025: $5.14 (46.2% of profit)
- Buybacks
- Dec 31, 2023: Repurchased $5.1 billion of shares in FY2023. ($5.1B)
- Dec 29, 2024: Repurchased $2.4 billion of shares in FY2024. ($2.4B)
- Dec 28, 2025: Repurchased $6.0 billion of shares in FY2025, through open-market purchases under a systematic plan to meet compensation programs. No publicly announced program was in place in Q4 FY2025. ($6.0B)
- Sep 27, 2026: Repurchased $6.0 billion of shares in the first nine months of FY2026. ($6.0B)
- AuditorPricewaterhouseCoopers LLP, since 1920
- Credit ratingNot checked for this page.
Pfizer
- Dividends per shareFY2021: $1.57 (39.7% of profit) · FY2022: $1.61 (28.6% of profit) · FY2023: $1.65 (436.4% of profit) · FY2024: $1.69 (118.4% of profit) · FY2025: $1.72 (125.7% of profit)
- Buybacks
- Dec 31, 2022: Bought $2.0 billion of its own shares in Q1 2022, its last buyback. $3.3 billion of authorization remained on Nov 3, 2026, and Pfizer's 2026 guidance assumes no buybacks. ($2.0B)
- AuditorKPMG LLP
- Credit ratingMoody's and S&P, as stated in Pfizer's 10-Q: A2 and A, outlook Stable (Nov 3, 2026)
Sources: Johnson & Johnson S3, S1, S6, S31 · Pfizer S3, S1, S4, S12, S6
Risks only one page tracks
Risks whose type the other company's page does not list. Both pages track risks of these types: legal cases, competition, pricing, customer or supplier concentration, execution, debt. Every risk is on each company's page.
Johnson & Johnson
- Tariffs and trade (other)J&J said on Jan 21, 2026 that it expected about $500 million of MedTech tariff costs in 2026. It recorded about $0.2 billion of tariff recoveries in Q3 FY2026.
Pfizer
- COVID-19 revenue has fallen (demand)Comirnaty and Paxlovid fell from 56.1% of revenue in FY2022 to 10.8% in FY2025. They were $2.0 billion in the first nine months of 2026, against $4.2 billion a year earlier.
Key facts
- How does Johnson & Johnson make money compared with Pfizer?
- Johnson & Johnson's revenue by segment in FY2025: Innovative Medicine 64.1%, MedTech 35.9%. Pfizer's revenue by segment in FY2025: Primary Care 42.9%, Specialty Care 28.0%, Oncology 26.9%, Other business activities 2.2%.
- Which is bigger by revenue, Johnson & Johnson or Pfizer?
- Johnson & Johnson reported $94.2B of revenue in FY2025, and Pfizer reported $62.6B in FY2025.
- How much net income did Johnson & Johnson and Pfizer report?
- Johnson & Johnson reported net income of $26.8B in FY2025, and Pfizer reported $7.8B in FY2025.
- How much of every $100 did Johnson & Johnson and Pfizer keep as net income?
- Johnson & Johnson kept $26.2 of every $100 that came in during FY2025, and Pfizer kept $12.4 in FY2025 (Cityfort calculation from each company's annual report).
- How much debt and cash do Johnson & Johnson and Pfizer have?
- Johnson & Johnson had $44.7B of debt and $17.2B of cash and investments on Sep 27, 2026. Pfizer had $62.7B of debt and $14.3B of cash and investments on Sep 27, 2026.
- When do Johnson & Johnson's and Pfizer's fiscal years end?
- Johnson & Johnson: Sunday nearest the end of December. Pfizer: December 31 for US subsidiaries and November 30 for those abroad, so Q3 FY2026 ended Sep 27, 2026 in the US and Aug 23, 2026 abroad.
Sources: Johnson & Johnson S3, S1, S6, S9 · Pfizer S3, S2, S1, S6, S9, S4
Built from each company's page. Johnson & Johnson updated Nov 6, 2026; Pfizer updated Nov 6, 2026.
Sources
Johnson & Johnson
- S1Form 10-K, fiscal year 2025 (ended December 28, 2025), Johnson & Johnson (SEC EDGAR), Feb 11, 2026
- S3Form 10-K, fiscal year 2023 (ended December 31, 2023), Johnson & Johnson (SEC EDGAR), Feb 16, 2024
- S6Form 10-Q, Q3 FY2026 (quarter ended September 27, 2026), Johnson & Johnson (SEC EDGAR), Oct 21, 2026
- S7Form 10-Q, Q2 FY2026 (quarter ended June 28, 2026), Johnson & Johnson (SEC EDGAR), Jul 23, 2026
- S8Form 10-Q, Q1 FY2026 (quarter ended March 29, 2026), Johnson & Johnson (SEC EDGAR), Apr 22, 2026
- S9Form 10-Q, Q3 FY2025 (quarter ended September 28, 2025), Johnson & Johnson (SEC EDGAR), Oct 22, 2025
- S10Form 10-Q, Q2 FY2025 (quarter ended June 29, 2025), Johnson & Johnson (SEC EDGAR), Jul 24, 2025
- S13Earnings release, Q3 FY2026 (Form 8-K, Exhibit 99.1), Johnson & Johnson (SEC EDGAR), Oct 13, 2026
- S14Earnings financial schedules, Q3 FY2026 (Form 8-K, Exhibit 99.2), Johnson & Johnson (SEC EDGAR), Oct 13, 2026
- S16Earnings financial schedules, Q2 FY2026 (Form 8-K, Exhibit 99.2), Johnson & Johnson (SEC EDGAR), Jul 15, 2026
- S18Earnings financial schedules, Q1 FY2026 (Form 8-K, Exhibit 99.2), Johnson & Johnson (SEC EDGAR), Apr 14, 2026
- S20Earnings financial schedules, Q4 FY2025 (Form 8-K, Exhibit 99.2), Johnson & Johnson (SEC EDGAR), Jan 21, 2026
- S22Earnings financial schedules, Q3 FY2025 (Form 8-K, Exhibit 99.2), Johnson & Johnson (SEC EDGAR), Oct 14, 2025
- S31Proxy statement (DEF 14A), 2026 annual meeting, record date February 24, 2026, Johnson & Johnson (SEC EDGAR), Mar 11, 2026
- S33Form 8-K, Item 7.01: Firefly Bio acquisition, Sail Biomedicines collaboration, updated 2026 guidance, Johnson & Johnson (SEC EDGAR), Jul 29, 2026
- S42Schedule 13G, Vanguard Capital Management, 180,631,228 shares, event March 31, 2026, Vanguard Capital Management (SEC EDGAR), May 1, 2026
- S45Q4 2025 earnings call transcript, January 21, 2026 (LSEG StreetEvents, posted on J&J investor site), Johnson & Johnson (investor relations), Jan 21, 2026
Pfizer
- S1Form 10-K for fiscal year 2025 (ended Dec 31, 2025), Pfizer Inc. (SEC EDGAR), Feb 26, 2026
- S2Form 10-K for fiscal year 2024, Pfizer Inc. (SEC EDGAR), Feb 27, 2025
- S3Form 10-K for fiscal year 2023, Pfizer Inc. (SEC EDGAR), Feb 22, 2024
- S4Form 10-K for fiscal year 2022, Pfizer Inc. (SEC EDGAR), Feb 23, 2023
- S6Form 10-Q for Q3 FY2026 (ended Sep 27, 2026), Pfizer Inc. (SEC EDGAR), Nov 3, 2026
- S7Form 10-Q for Q2 FY2026 (ended Jun 28, 2026), Pfizer Inc. (SEC EDGAR), Aug 4, 2026
- S8Form 10-Q for Q1 FY2026 (ended Mar 29, 2026), Pfizer Inc. (SEC EDGAR), May 5, 2026
- S9Form 10-Q for Q3 FY2025 (ended Sep 28, 2025), Pfizer Inc. (SEC EDGAR), Nov 4, 2025
- S12Earnings release for Q3 FY2026 (8-K Exhibit 99), Pfizer Inc. (SEC EDGAR), Nov 3, 2026
- S13Earnings release for Q2 FY2026 (8-K Exhibit 99), Pfizer Inc. (SEC EDGAR), Aug 4, 2026
- S14Earnings release for Q1 FY2026 (8-K Exhibit 99), Pfizer Inc. (SEC EDGAR), May 5, 2026
- S15Earnings release for Q4 FY2025 (8-K Exhibit 99), Pfizer Inc. (SEC EDGAR), Feb 3, 2026
- S16Earnings release for Q3 FY2025 (8-K Exhibit 99), Pfizer Inc. (SEC EDGAR), Nov 4, 2025
- S202026 proxy statement (DEF 14A), Pfizer Inc. (SEC EDGAR), Mar 12, 2026
- S21Schedule 13G, Vanguard Capital Management (event Mar 31, 2026), Vanguard Capital Management (SEC EDGAR), May 1, 2026
- S278-K filed Nov 13, 2025: Metsera acquisition completed (Item 8.01), Pfizer Inc. (SEC EDGAR), Nov 13, 2025
- S32Moderna Form 10-K for fiscal 2025 (year ended December 31, 2025), Moderna, Inc. (SEC EDGAR), Feb 20, 2026
Disclaimer
For learning only. Cityfort is not a registered investment adviser or broker-dealer and does not recommend buying or selling any security. Prices shown are dated and may be out of date.
Investing in securities involves risk, including loss of capital. Before making any investment decision, do your own research and consider consulting a registered investment adviser or other qualified professional.
Cityfort, its owners and contributors may or may not hold securities of companies covered. Cityfort is not paid by any company it covers. Content is not an offer or solicitation to buy or sell any security, including in any initial public offering.
Read the positions policyRead the full disclaimerHide the full disclaimer
Cityfort publishes general educational content that explains how listed companies work. Cityfort is not registered with the US Securities and Exchange Commission or any state securities regulator as an investment adviser, and is not a broker-dealer or a member of FINRA. Cityfort does not provide investment, tax or legal advice, recommendations, ratings, price targets or any opinion on whether to buy, sell or hold any security. Nothing on the site is tailored to any person's circumstances.
All information is taken from publicly available sources, mainly company filings with the SEC, which are listed on each page with dates. We work to keep it accurate and correct errors publicly, but we do not guarantee that it is complete, accurate or up to date. Any market price or price-based ratio shown is dated, may be out of date by the time you read it, and is included only to explain concepts.
Statements by company management, including forward-looking statements and guidance, are reported as the company's statements, with their date and source; they are not our forecasts. Adjusted (non-GAAP) figures are the company's own measures and are shown next to the official (GAAP) figures.